FELINTRA (itraconazole) antifungal therapy for cats, introduced by SAVAVET, a division of SAVA Healthcare Limited
– Vinod Ramchandra Jadhav
PUNE, MAHARASHRA, INDIA, May 8, 2022 /EINPresswire.com/ — SAVA Healthcare Limited’s small animal health and welfare vertical division, SAVAVET, announced the launch of FELINTRA.
FELINTRA is a new and improved formulation of itraconazole, an antifungal used to treat fungal infections in cats.
“Itraconazole in FELINTRA is more readily available in target issues due to the addition of cyclodextrin or cyclic carbohydrates in the formulation. This overcomes the problem of itraconazole’s poor water solubility. Therefore, FELINTRA is unique,” said Vinod Ramchandra Jadhav, Chairman – SAVA Healthcare Limited.
An estimated 1 in 3 cats suffer from dermatophytosis, a superficial fungal infection of the skin, hair and nails. Dermatophytosis is contagious and zoonotic. Itraconazole is approved by the USFDA for the treatment of dermatophytosis caused by Microsporum canis in cats. It has a broad spectrum of activity against yeast and fungi, improved tissue penetration and residual activity, superior antifungal potency and fungicidal activity, and with a high margin of safety.
FELINTRA is a new and improved formulation of itraconazole that offers greater bioavailability. However, the poor oral solubility and stability of itraconazole as an oral solution are major problems with existing formulations. FELINTRA is an itraconazole 10 mg/ml oral solution indicated for the treatment of dermatophytosis in cats caused by Microsporum canis. The recommended dose is 5 mg/kg/day as a pulse dose (weekly on/off) in cats.
SAVAVET, a division of SAVA Healthcare Ltd, is one of the largest and fastest growing healthcare companies dedicated to the lifelong health needs of pets. SAVAVET offers the most complete and comprehensive portfolio of medicines and wellness products to enrich the lives of companions.
Visit www.savavet.com for more information
About SAVA Healthcare Limited:
SAVA Healthcare, India is part of the SAVA Group with a WHO-GMP and PIC/s approved manufacturing facility in Gujarat, herbal extracts facility in Bengaluru and R&D facility in Pune. In addition, the Company is in the process of establishing a USFDA accredited formulation manufacturing facility near Indore. SAVA has four business segments – International Business, Contract Research and Manufacturing Services, Small Animal Health and Herbal Extract Business.
SAVA has a global presence through international businesses in North America, Eastern Europe, Asia, Central America, Africa and the CIS with human and veterinary pharmaceuticals. SAVA’s Contract Research & Manufacturing Services (CRAMS) business serves many Indian and global companies. The company is a leading manufacturer of nasal drug delivery platforms.
SAVAVET, the small animal healthcare business of SAVA Healthcare, is the market leader in prescription medicines for small animals in the Indian market.
For more informations:
SAVA Healthcare Limited
+91 20 3051 6113
email us here